Non-androgenic Anabolic Hormones Predict Risk Of Frailty: European Male Ageing Study Prospective Data.

Non-androgenic Anabolic Hormones Predict Risk Of Frailty: European Male Ageing Study Prospective Data.

J Clin Endocrinol Metab. 2017 05 09;:

Authors: Swiecicka A, Lunt M, Ahern TM, O'Neill TW, Bartfai GY, Casanueva FF, Forti G, Giwercman A, Han TS, Lean MEJ, Pendleton N, Punab M, Slowikowska-Hilczer J, Vanderschueren D, Huhtaniemi IT, Wu FCW, Rutter MK, the EMAS study group

Abstract
Context: Low levels of non-androgenic anabolic hormones have been linked with frailty but evidence is conflicting and prospective data are largely lacking.
Objective: To determine associations between non-androgenic anabolic hormones and prospective changes in frailty status.
Design/setting: 4.3-year prospective observational study of community-dwelling men participating in the European Male Ageing Study.
Participants: 3369 men aged 40-79 from 8 European centres.
Intervention: nil.
Main outcome measures: Frailty status was determined using frailty phenotype (FP, n=2114) and frailty index (FI, n=2444).
Analysis: Regression models assessed relationships between baseline levels of insulin-like growth factor-1 (IGF-1), its binding protein (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S), 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH), and changes in frailty status (worsening or improving frailty).
Results: The risk of worsening FP and FI decreased with 1 SD higher IGF-1, IGFBP-3 and 25OHD in models adjusted for age, BMI, centre and baseline frailty [IGF-1: OR for worsening FP: 0.82 (0.73, 0.93), % change in FI: -3.7% (-6.0, -1.5); IGFBP-3: 0.84 (0.75, 0.95), - 4.2% (-6.4, -2.0); 25OHD: 0.84 (0.75, 0.95), - 4.4%, (-6.7, -2.0)]. Relationships between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated with a lower risk of worsening FP in men >70 years old [OR: 0.57 (0.35, 0.92)] but not in younger men. PTH was unrelated to change in frailty status in any model.
Conclusions: These longitudinal data confirm the associations between non-androgenic anabolic hormones and the changes in frailty status. Interventional studies are needed to establish causality and determine therapeutic implications.

PMID: 28609827 [PubMed - as supplied by publisher]

http://ift.tt/2s09z7l